Zealand Pharma A/S Q2 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Thomas Schultz Bowers - Danske Bank A/S, Research Division - Analyst : A couple of obesity-related questions. So firstly, an overall strategic consideration here in the wake of the [V-Go] SELECT trial. Is there anything that has sort of made you look differently on your proprietary pipeline in the wake of this top line results? And then just on the amylin, so now you have a number of very interesting data early, maybe also a little bit early to call before we have the 16-week data readout. But still, is there any way -- do you actually see a potential for a meaningful weight loss with the big clinical and currently available clinical data? And I mean, of course, as potential stand-alone products, so maybe comparable to cure GLP-1. What do you see here as actually a potential weight loss after 1 year? And then just on dapiglutide. So sequence derived from GLP-2 peptide backbone, can you maybe just comment -- maybe I've just missed it, but can you comment on the actual bias towards each receptor? So just like you have said with, I think it's 8:1 with ratio with the GLP-1, so those are the BI 45 candidate. So anything you can disclose here?

Question: Thomas Schultz Bowers - Danske Bank A/S, Research Division - Analyst : Great. And maybe if I just may sneak in one additional question just on BI 45, so the Phase III, are you able to give us any color on the design? Just if there's anything that sort of materially differ from what we have seen with the [V-Go] and [peptide] and also in relation to whether there are some issues with the [glepaglutide] part, any special requests from the FDA that you are aware of?